Mirum Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 69.55 million compared to USD 27.91 million a year ago. Net loss was USD 33.15 million compared to USD 36.43 million a year ago.
For the full year, revenue was USD 186.37 million compared to USD 77.06 million a year ago. Net loss was USD 160.91 million compared to USD 135.67 million a year ago. Basic loss per share from continuing operations was USD 3.94 compared to USD 4.01 a year ago. Diluted loss per share from continuing operations was USD 3.94 compared to USD 4.01 a year ago.